UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $76.21 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 12.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 212,657 shares of the biotechnology company’s stock after selling 31,298 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.48% of United Therapeutics worth $76,206,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in UTHR. ClariVest Asset Management LLC boosted its stake in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the period. V Square Quantitative Management LLC acquired a new stake in shares of United Therapeutics in the second quarter worth $30,000. Innealta Capital LLC bought a new position in United Therapeutics during the second quarter worth $33,000. USA Financial Formulas bought a new position in United Therapeutics during the third quarter worth $33,000. Finally, Brooklyn Investment Group acquired a new position in United Therapeutics during the 3rd quarter valued at $33,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Down 0.1 %

Shares of UTHR stock opened at $370.12 on Tuesday. The company has a market capitalization of $16.53 billion, a P/E ratio of 16.27, a P/E/G ratio of 1.08 and a beta of 0.56. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The firm has a 50-day moving average price of $367.77 and a 200 day moving average price of $336.09.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.38 earnings per share. As a group, research analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $13,485,785.60. The trade was a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Judy D. Olian sold 1,750 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the sale, the director now directly owns 5,655 shares in the company, valued at $2,332,574.40. This trade represents a 23.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 119,442 shares of company stock valued at $44,577,770. 11.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Argus boosted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. TD Cowen boosted their price target on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, HC Wainwright raised their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.